Squamous Cell Carcinoma of the Oropharynx Clinical Trial
Official title:
Circulating Tumor Modified HPV DNA-Guided Radiotherapy De-intensification of the Elective Neck (RaDEN) in Squamous Cell Carcinoma of the Head and Neck
The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
In squamous cell carcinomas of the head and neck, regional recurrence is rare within lymph node stations treated with elective radiation. However, radiotherapy to the neck is toxic, and leads to a variety of unpleasant side effects, especially coupled with concurrent systemic therapy. There is growing evidence from previous studies showing that lower radiation doses may be adequate in preventing locoregional recurrence of disease. The hypothesis is that lower dose of radiation will have equal effectiveness but less toxicity than standard approaches for the treatment of squamous cell carcinomas of the head and neck. The study evaluates the effectiveness and safety of reduced dose radiotherapy for definitive and adjuvant treatment of Human papillomavirus (HPV) positive oropharyngeal squamous cell carcinomas. Participants will be treated with a radiation therapy regimen that has a lower dose to less tissue area (dose and volume de-escalation) than standard of care radiation therapy. The dosing will be determined by whether concurrent chemotherapy will be given, results from on treatment HPV blood test called NavDx, physical exam, and imaging. On treatment NavDx results indicating a slow (non-rapid) response to the treatment will receive an additional boost of radiation. Routine NavDx testing will be performed to assess treatment response and recurrence. Participants will also be asked to complete surveys about overall health and wellbeing. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03669718 -
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
|
Phase 2 | |
| Withdrawn |
NCT01586182 -
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04151134 -
Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
|
||
| Not yet recruiting |
NCT06380686 -
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
|
||
| Recruiting |
NCT05119036 -
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04031534 -
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
| Terminated |
NCT02552550 -
Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
|
||
| Active, not recruiting |
NCT04398524 -
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
|
Phase 2 | |
| Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
| Completed |
NCT01663259 -
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
|
N/A | |
| Recruiting |
NCT04104945 -
p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)
|
N/A | |
| Not yet recruiting |
NCT06061705 -
Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
|
N/A | |
| Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06112535 -
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
|
N/A | |
| Completed |
NCT01921426 -
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
|
Phase 1 | |
| Completed |
NCT01181648 -
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
|
||
| Recruiting |
NCT05918510 -
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
|
||
| Recruiting |
NCT05894083 -
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
|
Phase 2 |